Invasive  ||| S:0 E:9 ||| JJ
mycoses ||| S:9 E:16 ||| NN
:  ||| S:16 E:18 ||| :
diagnostic  ||| S:18 E:29 ||| JJ
challenges  ||| S:29 E:40 ||| NNS
Despite  ||| S:40 E:48 ||| IN
the  ||| S:48 E:52 ||| DT
availability  ||| S:52 E:65 ||| NN
of  ||| S:65 E:68 ||| IN
newer  ||| S:68 E:74 ||| JJR
antifungal  ||| S:74 E:85 ||| JJ
drugs ||| S:85 E:90 ||| NNS
,  ||| S:90 E:92 ||| ,
outcomes  ||| S:92 E:101 ||| NNS
for  ||| S:101 E:105 ||| IN
patients  ||| S:105 E:114 ||| NNS
with  ||| S:114 E:119 ||| IN
invasive  ||| S:119 E:128 ||| JJ
fungal  ||| S:128 E:135 ||| JJ
infections  ||| S:135 E:146 ||| NNS
( ||| S:146 E:147 ||| -LRB-
IFIs ||| S:147 E:151 ||| NNP
)  ||| S:151 E:153 ||| -RRB-
continue  ||| S:153 E:162 ||| VBP
to  ||| S:162 E:165 ||| TO
be  ||| S:165 E:168 ||| VB
poor ||| S:168 E:172 ||| JJ
,  ||| S:172 E:174 ||| ,
in  ||| S:174 E:177 ||| IN
large  ||| S:177 E:183 ||| JJ
part  ||| S:183 E:188 ||| NN
due  ||| S:188 E:192 ||| JJ
to  ||| S:192 E:195 ||| TO
delayed  ||| S:195 E:203 ||| JJ
diagnosis  ||| S:203 E:213 ||| NN
and  ||| S:213 E:217 ||| CC
initiation  ||| S:217 E:228 ||| NN
of  ||| S:228 E:231 ||| IN
appropriate  ||| S:231 E:243 ||| JJ
antifungal  ||| S:243 E:254 ||| JJ
therapy ||| S:254 E:261 ||| NN
.  ||| S:261 E:263 ||| .
Standard  ||| S:263 E:272 ||| JJ
histopathologic  ||| S:272 E:288 ||| JJ
diagnostic  ||| S:288 E:299 ||| JJ
techniques  ||| S:299 E:310 ||| NNS
are  ||| S:310 E:314 ||| VBP
often  ||| S:314 E:320 ||| RB
untenable  ||| S:320 E:330 ||| VBN
in  ||| S:330 E:333 ||| IN
at-risk  ||| S:333 E:341 ||| JJ
patients ||| S:341 E:349 ||| NNS
,  ||| S:349 E:351 ||| ,
and  ||| S:351 E:355 ||| CC
culture-based  ||| S:355 E:369 ||| JJ
diagnostics  ||| S:369 E:381 ||| NNS
typically  ||| S:381 E:391 ||| RB
are  ||| S:391 E:395 ||| VBP
too  ||| S:395 E:399 ||| RB
insensitive  ||| S:399 E:411 ||| JJ
or  ||| S:411 E:414 ||| CC
nonspecific ||| S:414 E:425 ||| NN
,  ||| S:425 E:427 ||| ,
or  ||| S:427 E:430 ||| CC
provide  ||| S:430 E:438 ||| VB
results  ||| S:438 E:446 ||| NNS
after  ||| S:446 E:452 ||| IN
too  ||| S:452 E:456 ||| RB
long  ||| S:456 E:461 ||| RB
a  ||| S:461 E:463 ||| DT
delay  ||| S:463 E:469 ||| NN
for  ||| S:469 E:473 ||| IN
optimal  ||| S:473 E:481 ||| JJ
IFI  ||| S:481 E:485 ||| NNP
management ||| S:485 E:495 ||| NN
.  ||| S:495 E:497 ||| .
Newer  ||| S:497 E:503 ||| JJR
surrogate  ||| S:503 E:513 ||| JJ
markers  ||| S:513 E:521 ||| NN
of  ||| S:521 E:524 ||| IN
IFIs  ||| S:524 E:529 ||| JJ
with  ||| S:529 E:534 ||| IN
improved  ||| S:534 E:543 ||| JJ
sensitivity  ||| S:543 E:555 ||| NN
and  ||| S:555 E:559 ||| CC
specificity  ||| S:559 E:571 ||| NNS
are  ||| S:571 E:575 ||| VBP
needed  ||| S:575 E:582 ||| VBN
to  ||| S:582 E:585 ||| TO
enable  ||| S:585 E:592 ||| VB
earlier  ||| S:592 E:600 ||| JJR
diagnosis  ||| S:600 E:610 ||| NN
and ||| S:610 E:613 ||| CC
,  ||| S:613 E:615 ||| ,
ideally ||| S:615 E:622 ||| NN
,  ||| S:622 E:624 ||| ,
to  ||| S:624 E:627 ||| TO
provide  ||| S:627 E:635 ||| VB
prognostic  ||| S:635 E:646 ||| JJ
information  ||| S:646 E:658 ||| NN
and ||| S:658 E:661 ||| CC
/ ||| S:661 E:662 ||| NNP
or  ||| S:662 E:665 ||| CC
permit  ||| S:665 E:672 ||| VB
therapeutic  ||| S:672 E:684 ||| JJ
monitoring ||| S:684 E:694 ||| NN
.  ||| S:694 E:696 ||| .
Surrogate  ||| S:696 E:706 ||| JJ
assays  ||| S:706 E:713 ||| NN
should  ||| S:713 E:720 ||| MD
also  ||| S:720 E:725 ||| RB
be  ||| S:725 E:728 ||| VB
accessible  ||| S:728 E:739 ||| JJ
and  ||| S:739 E:743 ||| CC
easy  ||| S:743 E:748 ||| JJ
to  ||| S:748 E:751 ||| TO
implement  ||| S:751 E:761 ||| VB
in  ||| S:761 E:764 ||| IN
the  ||| S:764 E:768 ||| DT
hospital ||| S:768 E:776 ||| NN
.  ||| S:776 E:778 ||| .
Several  ||| S:778 E:786 ||| JJ
nonculture-based  ||| S:786 E:803 ||| JJ
assays  ||| S:803 E:810 ||| NN
of  ||| S:810 E:813 ||| IN
newer  ||| S:813 E:819 ||| JJR
surrogates  ||| S:819 E:830 ||| NNS
are  ||| S:830 E:834 ||| VBP
making  ||| S:834 E:841 ||| VBG
their  ||| S:841 E:847 ||| PRP$
way  ||| S:847 E:851 ||| NN
into  ||| S:851 E:856 ||| IN
the  ||| S:856 E:860 ||| DT
medical  ||| S:860 E:868 ||| JJ
setting  ||| S:868 E:876 ||| NN
or  ||| S:876 E:879 ||| CC
are  ||| S:879 E:883 ||| VBP
currently  ||| S:883 E:893 ||| RB
under  ||| S:893 E:899 ||| IN
investigation ||| S:899 E:912 ||| NN
.  ||| S:912 E:914 ||| .
These  ||| S:914 E:920 ||| DT
new  ||| S:920 E:924 ||| JJ
or  ||| S:924 E:927 ||| CC
up-and-coming  ||| S:927 E:941 ||| JJ
surrogates  ||| S:941 E:952 ||| NNS
include  ||| S:952 E:960 ||| VBP
antigens ||| S:960 E:968 ||| RB
/ ||| S:968 E:969 ||| CD
antibodies  ||| S:969 E:980 ||| NNS
( ||| S:980 E:981 ||| -LRB-
mannan  ||| S:981 E:988 ||| NN
and  ||| S:988 E:992 ||| CC
antimannan  ||| S:992 E:1003 ||| JJ
antibodies ||| S:1003 E:1013 ||| NNS
)  ||| S:1013 E:1015 ||| -RRB-
or  ||| S:1015 E:1018 ||| CC
fungal  ||| S:1018 E:1025 ||| JJ
metabolites  ||| S:1025 E:1037 ||| NNS
( ||| S:1037 E:1038 ||| -LRB-
d-arabinitol ||| S:1038 E:1050 ||| NNP
)  ||| S:1050 E:1052 ||| -RRB-
for  ||| S:1052 E:1056 ||| IN
detection  ||| S:1056 E:1066 ||| NN
of  ||| S:1066 E:1069 ||| IN
invasive  ||| S:1069 E:1078 ||| JJ
candidiasis ||| S:1078 E:1089 ||| NN
,  ||| S:1089 E:1091 ||| ,
the  ||| S:1091 E:1095 ||| DT
Aspergillus  ||| S:1095 E:1107 ||| JJ
cell  ||| S:1107 E:1112 ||| NN
wall  ||| S:1112 E:1117 ||| NN
component  ||| S:1117 E:1127 ||| NN
galactomannan  ||| S:1127 E:1141 ||| VBZ
used  ||| S:1141 E:1146 ||| VBN
to  ||| S:1146 E:1149 ||| TO
detect  ||| S:1149 E:1156 ||| VB
invasive  ||| S:1156 E:1165 ||| JJ
aspergillosis ||| S:1165 E:1178 ||| NN
,  ||| S:1178 E:1180 ||| ,
or  ||| S:1180 E:1183 ||| CC
the  ||| S:1183 E:1187 ||| DT
fungal  ||| S:1187 E:1194 ||| JJ
cell  ||| S:1194 E:1199 ||| NN
wall  ||| S:1199 E:1204 ||| NN
component  ||| S:1204 E:1214 ||| NN
and  ||| S:1214 E:1218 ||| CC
panfungal  ||| S:1218 E:1228 ||| JJ
marker  ||| S:1228 E:1235 ||| JJ
Î²-glucan ||| S:1235 E:1243 ||| NN
.  ||| S:1243 E:1245 ||| .
In  ||| S:1245 E:1248 ||| IN
addition ||| S:1248 E:1256 ||| NN
,  ||| S:1256 E:1258 ||| ,
progress  ||| S:1258 E:1267 ||| NN
continues  ||| S:1267 E:1277 ||| VBZ
with  ||| S:1277 E:1282 ||| IN
use  ||| S:1282 E:1286 ||| NN
of  ||| S:1286 E:1289 ||| IN
polymerase  ||| S:1289 E:1300 ||| JJ
chain  ||| S:1300 E:1306 ||| NN
reaction-  ||| S:1306 E:1316 ||| NN
or  ||| S:1316 E:1319 ||| CC
other  ||| S:1319 E:1325 ||| JJ
nucleic  ||| S:1325 E:1333 ||| JJ
acid-  ||| S:1333 E:1339 ||| JJ
or  ||| S:1339 E:1342 ||| CC
molecular-based  ||| S:1342 E:1358 ||| JJ
assays  ||| S:1358 E:1365 ||| NN
for  ||| S:1365 E:1369 ||| IN
diagnosis  ||| S:1369 E:1379 ||| NN
of  ||| S:1379 E:1382 ||| IN
either  ||| S:1382 E:1389 ||| DT
specific  ||| S:1389 E:1398 ||| JJ
or  ||| S:1398 E:1401 ||| CC
generic  ||| S:1401 E:1409 ||| JJ
IFIs ||| S:1409 E:1413 ||| NN
,  ||| S:1413 E:1415 ||| ,
although  ||| S:1415 E:1424 ||| IN
the  ||| S:1424 E:1428 ||| DT
various  ||| S:1428 E:1436 ||| JJ
methods  ||| S:1436 E:1444 ||| NNS
must  ||| S:1444 E:1449 ||| MD
be  ||| S:1449 E:1452 ||| VB
better  ||| S:1452 E:1459 ||| RBR
standardized  ||| S:1459 E:1472 ||| JJ
before  ||| S:1472 E:1479 ||| IN
any  ||| S:1479 E:1483 ||| DT
of  ||| S:1483 E:1486 ||| IN
these  ||| S:1486 E:1492 ||| DT
approaches  ||| S:1492 E:1503 ||| NNS
can  ||| S:1503 E:1507 ||| MD
be  ||| S:1507 E:1510 ||| VB
more  ||| S:1510 E:1515 ||| RBR
fully  ||| S:1515 E:1521 ||| RB
implemented  ||| S:1521 E:1533 ||| VBN
into  ||| S:1533 E:1538 ||| IN
the  ||| S:1538 E:1542 ||| DT
medical  ||| S:1542 E:1550 ||| JJ
setting ||| S:1550 E:1557 ||| NN
.  ||| S:1557 E:1559 ||| .
Investigators  ||| S:1559 E:1573 ||| NNS
are  ||| S:1573 E:1577 ||| VBP
also  ||| S:1577 E:1582 ||| RB
beginning  ||| S:1582 E:1592 ||| VBG
to  ||| S:1592 E:1595 ||| TO
explore  ||| S:1595 E:1603 ||| VB
the  ||| S:1603 E:1607 ||| DT
possibility  ||| S:1607 E:1619 ||| NN
of  ||| S:1619 E:1622 ||| IN
combining  ||| S:1622 E:1632 ||| VBG
newer  ||| S:1632 E:1638 ||| JJR
surrogate  ||| S:1638 E:1648 ||| JJ
markers  ||| S:1648 E:1656 ||| NN
with  ||| S:1656 E:1661 ||| IN
each  ||| S:1661 E:1666 ||| DT
other  ||| S:1666 E:1672 ||| JJ
or  ||| S:1672 E:1675 ||| CC
with  ||| S:1675 E:1680 ||| IN
more  ||| S:1680 E:1685 ||| RBR
standard  ||| S:1685 E:1694 ||| JJ
diagnostic  ||| S:1694 E:1705 ||| JJ
approaches  ||| S:1705 E:1716 ||| NNS
to  ||| S:1716 E:1719 ||| TO
improve  ||| S:1719 E:1727 ||| VB
sensitivity ||| S:1727 E:1738 ||| NN
,  ||| S:1738 E:1740 ||| ,
specificity ||| S:1740 E:1751 ||| NN
,  ||| S:1751 E:1753 ||| ,
and  ||| S:1753 E:1757 ||| CC
capacity  ||| S:1757 E:1766 ||| NN
for  ||| S:1766 E:1770 ||| IN
earlier  ||| S:1770 E:1778 ||| JJR
diagnosis ||| S:1778 E:1787 ||| NN
,  ||| S:1787 E:1789 ||| ,
at  ||| S:1789 E:1792 ||| IN
a  ||| S:1792 E:1794 ||| DT
time  ||| S:1794 E:1799 ||| NN
when  ||| S:1799 E:1804 ||| WRB
fungal  ||| S:1804 E:1811 ||| JJ
burden  ||| S:1811 E:1818 ||| NN
is  ||| S:1818 E:1821 ||| VBZ
still  ||| S:1821 E:1827 ||| RB
relatively  ||| S:1827 E:1838 ||| RB
low  ||| S:1838 E:1842 ||| JJ
and  ||| S:1842 E:1846 ||| CC
more  ||| S:1846 E:1851 ||| RBR
responsive  ||| S:1851 E:1862 ||| JJ
to  ||| S:1862 E:1865 ||| TO
antifungal  ||| S:1865 E:1876 ||| VB
therapy ||| S:1876 E:1883 ||| NN
.  ||| S:1883 E:1885 ||| .
